http://www.earningsimpact.com/Transcript/81948/ARIA/Ariad-Pharmaceuticals%2c-Inc----33rd-Annual-William-Blair-Growth-Stock-Conference Quotes from the transcript.. "And in fact, we announced just this morning the beginning of the trial and new indication which I will describe a little bit later. But a very important trial that's ongoing for Iclusig still in leukemia is the EPIC trial that's testing the drug instead of in the resistant population for which we have U.S. Approval in the newly diagnosed CML population, where the potential for a drug with Iclusig's properties is very great to have a game changing activity and duration of response in newly diagnosed patients. That trial is advancing well and the next readout for that trial will be around third quarter next year which will be the first look at an interim analysis of efficacy. Our second drug AP26113, I'll call it 113 will begin a pivotal trial in its target population of resistant ALK-positive lung cancer in the next quarter. And at the same time we have on ongoing phase II trial that has just evolved from the Phase I trial is completed that is looking at the series of cohorts of patients that have potential susceptibility to 113 and then includes an important family of patients with EGFR-mutation, so that's another lung cancer target. In parallel that we continue to work internally on our pipeline."
